A Study of SPY072 in Rheumatic Disease

Inclusion Criteria:

For rheumatoid arthritis:

• Moderate-to-severely active RA as defined by the presence of ≥4 swollen joints (based on 28 joint count) and ≥4 tender joints (based on 28 joint count) atScreening and Day 1.

• Documentation of ≥1 of the following:

1. Positive test results for rheumatoid factor or anti-citrullinated peptideantibodies at Screening, OR

2. Previous radiographs with bony erosions in hands or feet consistent with RA

• Inadequate response (defined as signs and symptoms of persistently active disease,loss of response, or intolerance) to one of the following:

1. ≥1 csDMARD treatment; OR

2. 1 bDMARD or 1 tsDMARD treatment (a total of 2 bDMARDs and/or tsDMARDs isexclusionary)

For axial spondyloarthritis:

• Moderate-to-severely active axSpA defined by BOTH of the following at Screening ANDDay 1:

1. BASDAI ≥4, AND

2. Back pain ≥4 (from BASDAI Item 2)

• hsCRP greater than the ULN per the central laboratory at Screening - Inadequateresponse (defined as signs and symptoms of persistently active disease, loss ofresponse, or intolerance) to one of the following:

1. 2 different NSAIDs given at the maximum tolerated dose for ≥4 weeks orintolerant to or has a contraindication to NSAID therapy; OR

2. 1 bDMARD (anti-TNF or anti-IL-17) or 1 tsDMARD treatment at an approved dosefor ≥12 weeks (a total of 2 bDMARDs and/or tsDMARDs is exclusionary)

For psoriatic arthritis:

• Day 1 TJC ≥3 out of 68 and SJC ≥3 out of 66 (dactylitis counts as 1 joint each)

• ≥1 active plaque psoriasis lesion and/or a documented history of psoriasis

• In adequate response (defined as signs and symptoms of persistently active disease,loss of response, or intolerance) to one of the following:

1. ≥1 NSAID treatment; AND

2. ≥1 csDMARD treatment; OR

3. 1 bDMARD or 1 tsDMARD treatment (a total of 2 bDMARDs and/or tsDMARDs isexclusionary)

Exclusion Criteria:

• Inadequate response to ≥2 or more bDMARDs and/or tsDMARDs

• Other autoimmune, rheumatologic, inflammatory diseases or pain-amplificationsyndromes that might confound the evaluations of efficacy of SPY072